Even After Anti-Androgen Therapy, Docetaxel Remains Useful in Prostate...

University of Colorado Cancer Center and collaborating institutions present results at 2016 Genitourinary Cancers Symposium showing that 40 percent of patients with castration-resistant metastatic...(PRWeb January 12, 2016)Read the full story at http://www.prweb.com/releases/2016/01/prweb13159325.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news